688238 和元生物
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-3.538-16.946-6.0492.5416.141
总资产报酬率 ROA (%)-2.656-13.167-5.0172.0884.906
投入资产回报率 ROIC (%)-2.969-14.951-5.5852.3025.409

边际利润分析
销售毛利率 (%)-36.442-37.808-6.37444.41151.336
营业利润率 (%)-111.804-125.106-75.90014.31823.847
息税前利润/营业总收入 (%)-110.958-125.825-83.8864.86520.619
净利润/营业总收入 (%)-112.607-129.834-62.40813.47621.282

收益指标分析
经营活动净收益/利润总额(%)102.87589.823100.11285.56677.949
价值变动净收益/利润总额(%)-1.045-0.0840.7435.5105.858
营业外收支净额/利润总额(%)0.6690.6960.101-0.201-0.020

偿债能力分析
流动比率 (X)1.6722.0932.9527.8365.453
速动比率 (X)1.4721.8692.6957.4845.131
资产负债率 (%)26.06223.86220.93813.00927.367
带息债务/全部投入资本 (%)14.2289.1676.4201.0508.557
股东权益/带息债务 (%)572.214942.8691,398.7449,037.552956.198
股东权益/负债合计 (%)283.752319.115377.573668.693265.397
利息保障倍数 (X)-69.396-793.20410.606-0.516-6.398

营运能力分析
应收账款周转天数 (天)137.841106.803129.20465.89536.964
存货周转天数 (天)91.58981.377121.037121.92096.105